ARGX

721

+0.39%↑

SHL.DE

35.12

+0.66%↑

PHIA

22.99

+1.05%↑

FRE

36.47

-0.65%↓

SRT3

247.8

+3.51%↑

ARGX

721

+0.39%↑

SHL.DE

35.12

+0.66%↑

PHIA

22.99

+1.05%↑

FRE

36.47

-0.65%↓

SRT3

247.8

+3.51%↑

ARGX

721

+0.39%↑

SHL.DE

35.12

+0.66%↑

PHIA

22.99

+1.05%↑

FRE

36.47

-0.65%↓

SRT3

247.8

+3.51%↑

ARGX

721

+0.39%↑

SHL.DE

35.12

+0.66%↑

PHIA

22.99

+1.05%↑

FRE

36.47

-0.65%↓

SRT3

247.8

+3.51%↑

ARGX

721

+0.39%↑

SHL.DE

35.12

+0.66%↑

PHIA

22.99

+1.05%↑

FRE

36.47

-0.65%↓

SRT3

247.8

+3.51%↑

Kodu・Aktsiate loetelu・Sanofi SA
Search

Sanofi SA

Avatud

SektorTervishoid

75.3 -1.1

Osta

Hinna uuendus 29. mai 2026, 14:53 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

75.12

Max

76.91

Põhinäitajad

By Trading Economics

Sissetulek

-394M

1.6B

Müük

-12B

11B

P/E

Sektori keskmine

19.273

50.102

Aktsiakasum

1.34

Kasumimarginaal

14.354

Töötajad

74,846

EBITDA

1.5B

2.7B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+23.44% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

-7.5B

91B

Eelmine avamishind

76.4

Eelmine sulgemishind

75.3

Uudiste sentiment

By Acuity

32%

68%

76 / 344 Pingereas Healthcare

Sanofi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 09:03 UTC

Tulu

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

DJ

Loe

29. apr 2026, 05:27 UTC

Tulu

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

DJ

Loe

23. apr 2026, 06:12 UTC

Tulu

Sanofi Posts Higher Sales Amid Leadership Transition

DJ

Loe

27. mai 2026, 20:34 UTC

Omandamised, ülevõtmised, äriostud

Webster Financial Stockholders Approve Sale to Banco Santander

DJ

Loe

7. mai 2026, 06:47 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

DJ

Loe

1. mai 2026, 06:14 UTC

Omandamised, ülevõtmised, äriostud

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

DJ

Loe

1. mai 2026, 06:13 UTC

Omandamised, ülevõtmised, äriostud

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

DJ

Loe

1. mai 2026, 06:12 UTC

Omandamised, ülevõtmised, äriostud

Santander UK Financed Deal From Existing Cash Resources

DJ

Loe

1. mai 2026, 06:08 UTC

Omandamised, ülevõtmised, äriostud

Santander UK Announced Key Terms of Deal July 2025

DJ

Loe

1. mai 2026, 06:03 UTC

Omandamised, ülevõtmised, äriostud

Santander UK Buys TSB Banking for GBP2.65B

DJ

Loe

1. mai 2026, 06:02 UTC

Omandamised, ülevõtmised, äriostud

Santander UK Buys TSB Banking Group

DJ

Loe

29. apr 2026, 12:01 UTC

Tulu

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

DJ

Loe

29. apr 2026, 06:27 UTC

Market Talk
Tulu

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

DJ

Loe

29. apr 2026, 04:55 UTC

Tulu

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

DJ

Loe

29. apr 2026, 04:55 UTC

Tulu

Santander 1Q Loan Loss Provisions EUR3.225B

DJ

Loe

29. apr 2026, 04:54 UTC

Tulu

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

DJ

Loe

29. apr 2026, 04:54 UTC

Tulu

Santander 1Q Operating Expenses EUR6.48B

DJ

Loe

29. apr 2026, 04:52 UTC

Tulu

Santander Backs 2028 View

DJ

Loe

29. apr 2026, 04:52 UTC

Tulu

Santander Backs 2026 View

DJ

Loe

29. apr 2026, 04:52 UTC

Tulu

Santander 1Q Underlying RoTE 15.2%

DJ

Loe

29. apr 2026, 04:51 UTC

Tulu

Santander End-1Q CET1 Ratio 14.4%

DJ

Loe

29. apr 2026, 04:51 UTC

Tulu

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

DJ

Loe

29. apr 2026, 04:51 UTC

Tulu

Santander 1Q Net Interest Income EUR11.02B

DJ

Loe

29. apr 2026, 04:50 UTC

Tulu

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

DJ

Loe

29. apr 2026, 04:50 UTC

Tulu

Santander 1Q Underlying Pft EUR3.56B

DJ

Loe

29. apr 2026, 04:49 UTC

Tulu

Santander 1Q Net Pft EUR5.455B

DJ

Loe

29. apr 2026, 04:49 UTC

Tulu

Analysts Saw Santander 1Q Rev EUR15.00B

DJ

Loe

29. apr 2026, 04:49 UTC

Tulu

Santander 1Q Rev EUR15.14B

DJ

Loe

27. apr 2026, 09:32 UTC

Market Talk
Tulu

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

DJ

Loe

27. apr 2026, 09:19 UTC

Market Talk

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Sanofi SA Prognoos

Hinnasiht

By TipRanks

23.44% tõus

12 kuu keskmine prognoos

Keskmine 95.223 EUR  23.44%

Kõrge 107 EUR

Madal 85 EUR

Põhineb 9 Wall Streeti analüütiku instrumendi Sanofi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

4

Osta

5

Hoia

0

Müü

Põhineb 9 analüütiku instrumendi Sanofi SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

76 / 344 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Muud aktsiad sektorist

ARGX

Argenx SE

721

↑ +0.39%

SHL.DE

Siemens Healthineers AG

35.12

↑ +0.66%

PHIA

Koninklijke Philips NV

22.99

↑ +1.05%

FRE

Fresenius SE & Co KGaA

36.47

↓-0.65%

SRT3

Sartorius AG

247.8

↑ +3.51%
help-icon Live chat